Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial.

ABSTRACT:

Background

Tumor invasion and metastasis are responsible for the majority of cancer-related deaths. The identification of molecules involved in these processes is crucial to design effective treatments that can halt the progression of cancer. To spread and metastasize, tumor cells must restructure their cytoskeleton and emit protrusions. A key molecule in this process of creating these invading structures is Fascin1, the main protein involved in the formation of actin cytoskeleton bundles and a consistent marker of bad prognosis in several types of cancer. Recent studies have shown that imipramine, an FDA- and EMA-approved antidepressant, can block Fascin1and prevent the formation of actin bundles, making it a promising candidate for the treatment of Fascin1-expressing cancers. As

SUBMITTER: Asensi-Canto A 

PROVIDER: S-EPMC10570506 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature